Building on the broad experience of its management, we have established a well-balanced portfolio of cancer therapies with our lead humanized antibody product, CT-011, in Phase II clinical testing. Our products are antibodies and peptide-based vaccines designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner. An extensive portfolio of issued patents and pending patent applications worldwide protects all our products and their anticipated medical uses.

Our Products

The company’s products are antibodies and peptide-therapeutics designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner.

Our lead product, CT-011, is a humanized monoclonal antibody that interacts with PD-1, a B7 receptor-family-associated protein and exhibits efficient anti-cancer immune response against a wide variety of mouse and human tumors. A multi-center Phase II clinical study in patients with Diffuse Large B cell lymphoma has been initiated in the US and Israel.

News

Teva will invest up to additional $10.5 Million in CureTech.

CureTech announces receipt of a Notice of Allowance from the US Patent and Trademark Office

Teva Pharmaceuticals To Invest $6 Million In CureTech